Article

Non-Genetic Mechanisms of Fractional Resistance to Abemaciclib in Dedifferentiated Liposarcoma

2026-05-26

Abstract excerpt

Dedifferentiated liposarcoma is a rare mesenchymal malignancy driven by amplification of chromosome 12q13-15, which includes the oncogenes CDK4 and MDM2. CDK4 amplification provides a rationale for targeted therapy with CDK4/6 inhibitors, and abemaciclib has shown the most durable activity reported to date in this disease. Clinical responses, however, are incomplete and often transient, and the cellular features t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1964f2db-3944-5976-97e2-e0e9cc97b3d0
DOI: 10.64898/2026.05.22.727236

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Non-Genetic Mechanisms of Fractional Resistance to Abemaciclib in Dedifferentiated LiposarcomaDOI 10.64898/2026.05.22.727236Read

Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In VivoSemantic proximity Read

Spatially-resolved single cell atlas of liposarcoma reveals lineage hierarchies, immune niches, and regulatory circuitsSemantic proximity Read

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingSemantic proximity Read

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversSemantic proximity Read

CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic TargetsSemantic proximity Read

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSemantic proximity Read

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.Semantic proximity Read

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNASemantic proximity Read

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsSemantic proximity Read

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read